pISSN 2234-3806eISSN 2234-3814
Table. 3.
Transfection efficiency of CRISPR/Cas9 system in NK cells
| Cell source | Genetic modification system | Genetic material | Transfection efficiency | Reference |
|---|---|---|---|---|
| Human primary NK cells | CRISPR/Cas9 (electroporation) | RNP for NKG2A KO | 13.8% | [39] |
| Human primary NK cells | CRISPR/Cas9 (electroporation) | RNP for CALHM2 KO | ~40% | [41] |
| NK92 | CRISPR/Cas9 (electroporation) | RNP for CALHM2 KO | ~60% | [41] |
| Mouse primary NK cells | CRISPR/Cas9 (electroporation) | RNP for CALHM2 KO | ~70% | [41] |
| Human primary NK cells | CRISPR/Cas9 and TcB transposon system (electroporation) | RNP for CISH KO | ~50% | [40] |
Abbreviations: clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9); NK, natural killer; RNP, ribonucleoprotein; KO, knockout; TcB; TcBuster.
Ann Lab Med 2025;45:146~159 https://doi.org/10.3343/alm.2024.0380
© Ann Lab Med